Welcome to our dedicated page for Enzolytics news (Ticker: ENZC), a resource for investors and traders seeking the latest updates and insights on Enzolytics stock.
Enzolytics, Inc. (ENZC) operates at the intersection of healthcare innovation and commercial strategy, focusing on medical device licensing, diagnostic technologies, and science-backed nutraceuticals. This news hub provides investors and industry observers with verified updates about the company’s strategic initiatives, intellectual property developments, and market expansions.
Our curated collection offers immediate access to ENZC’s press releases, including details on licensing agreements, acquisition strategies, and research advancements in immunotherapy and medical testing. Users will find updates on regulatory milestones, partnership announcements, and product distribution channels, all essential for understanding the company’s evolving role in healthcare innovation.
This resource is designed for efficient tracking of ENZC’s multifaceted operations, from its patented drug delivery systems to its defense of intellectual property in litigation matters. The content reflects the company’s commitment to merging scientific rigor with commercial viability across medical devices, bioactive compounds, and diagnostic solutions.
Bookmark this page for streamlined access to Enzolytics’ official communications, ensuring you remain informed about its progress in converting research into market-ready health technologies. Regular updates provide transparency into ENZC’s governance decisions and collaborative ventures within the global healthcare ecosystem.
Enzolytics (OTC PINK:ENZC) announced results from the Bulgarian Academy of Sciences' in vivo testing of Irreversible Pepsin Fraction (IPF) as an immunomodulator. The study, sponsored by Rosetta , found that IPF has a stimulating and modulating effect on innate and acquired immunity components, activating B, T, and NK cells, as well as macrophages. Notably, it increased B-regulatory cells, enhancing immune system control. The treatment showed no side effects, with 100% survival rate.
Additionally, a separate study by the Ministry of Health National Centre of Infectious and Parasitic Diseases in Bulgaria concluded that ENZC's exclusively licensed experimental cancer lyophilized pepsin treatment is effective in decreasing growth and spread of various cancer cells, including breast, colon, prostate, larynx, and small cell lung cancer.
Enzolytics, Inc. (OTC PINK:ENZC) has entered a three-year agreement with the Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences. The collaboration aims to accelerate the discovery of combined applications and commercialization of their technologies, focusing initially on combining Monoclonal Antibodies and Immune Therapeutic Proteins (ITP) for treating malignant antigens.
The agreement involves conducting future investigations, including pharmacokinetics, pre-clinical, and clinical trials. This partnership leverages the expertise of the Stephan Angeloff Institute of Microbiology (SAIM), which boasts a scientific staff of 82 and over 30 ongoing research projects funded by various international institutions.
Additionally, a recent study conducted at the Ministry of Health National Centre of Infectious and Parasitic Diseases in Sofia, Bulgaria, concluded that ENZC's patented experimental cancer lyophilized pepsin treatment is effective in decreasing the growth and spread of various cancer types, including breast, colon, prostate, larynx, and small cell lung cancer.
Enzolytics, Inc. (OTC PINK:ENZC) announced positive results from a study conducted at the National Centre of Infectious and Parasitic Diseases in Sofia, Bulgaria. The study concluded that the company's patented experimental cancer lyophilized pepsin treatment effectively reduces the growth and spread of cancer cells in various types of cancer, including breast, colon, prostate, larynx, and small cell lung cancer.
The report, authored by Associate Professor Petya Genova-Kalu and Professor Dr. Iva Hristova, states that the polypeptide complex of lyophilized pepsin causes cytopathological changes and significantly reduces the survival and proliferative activity of cancer cell cultures. The effect was observed to be time- and concentration-dependent. The scientists concluded that lyophilized pepsin has extremely promising biomedical potential.
Enzolytics, Inc. (OTC PINK:ENZC) has initiated a cooperative program with the Department of Immunology, Bulgarian Academy of Science's Stephan Angeloff Institute of Microbiology. This collaboration aims to expand the use of each other's technology, focusing on applied and strategic research in immunology for cancer, HIV/AIDS, diabetes, multiple sclerosis, and other diseases.
The Department of Immunology's research infrastructure includes state-of-the-art laboratory facilities and equipment for cell culture, animal breeding, flow cytometry, microscopy, and antibody production. The partnership is expected to enhance Enzolytics' exclusively licensed patented Cancer Immunotherapy treatment and potentially increase shareholder value through the combination of products and processes.
Enzolytics, Inc. (OTC PINK:ENZC) has entered into a 4-year Collaboration Agreement with Elimus , a Bulgarian company, for manufacturing, developing, and marketing nutraceutical products in North America. The agreement includes exclusive licensing of Elimus' product catalog, including VIP Power, in the licensed territory. Ownership of new products developed under this agreement will be shared equally.
Additionally, Enzolytics has won its litigation against Cimarron Capital and Kona Concepts, Inc. The company's only remaining legal issue is a pro se appeal by Dimatar Savov. Harry Zhabilov, CSO, emphasized the company's commitment to defending its IP rights, while CEO Steve Sharabura expressed relief that legacy lawsuits have been resolved, allowing the company to focus on growth.
Enzolytics Inc. (OTC PINK:ENZC) has announced its full support for Sagaliam Acquisition Corp's (SAGA) efforts to counter false claims made by NIKA Pharmaceutical and its CEO, Dimtar Savov. The dispute centers around patents for an Immunotherapy treatment of HIV/AIDS, which Enzolytics asserts are rightfully owned by Harry H. Zhabilov and the Zhabilov Trust. Virogentics, Inc., a wholly-owned subsidiary of Sagaliam, is stated to be the exclusive license holder of this intellectual property.
Steve Sharabura, Interim CEO of Enzolytics, emphasized the company's commitment to protecting shareholder value and ending what they describe as a 'travesty'. The press release highlights previous legal actions in US and Bulgarian courts, where Mr. Savov reportedly lost civil court cases and defaulted on licensing agreements.
Enzolytics announced a worldwide exclusive licensing agreement for US Patent #8067531-B2, aiming to use immunotherapy in treating cancer. The company plans to begin FDA in-vitro studies and leverage 'Right to Try Laws' for terminally ill stage four cancer patients. Enzolytics is also negotiating the acquisition of a GMP-standard pharmaceutical manufacturing facility in Bulgaria. Additionally, Sagaliam Acquisition Corp. (SAGA) is progressing toward an OTC listing, securing funding for audits, and filing patent applications for Multiple Sclerosis and immune system modulation treatments. SAGA is also coordinating the dividend distribution of shares to Enzolytics shareholders from a prior sale. The company remains focused on expanding its intellectual property portfolio and increasing consumer engagement through digital marketing.
Enzolytics (ENZC) and Sagaliam Acquisition Corp (SAGA) are negotiating a $6 million investment in the SPAD Project led by Dr. Tong of the International Cultural and Educational Exchange Foundation (ICEEF). The investment includes $3 million in cash and $3 million in stock for a 30% non-dilutable ownership in room temperature Single Photon Avalanche Diode (SPAD) technology. This cutting-edge technology detects single photons at room temperature, significantly enhancing efficiency and reducing costs. It has potential applications in medical radiology, Lidar, military, space, and security systems. Silicon photonics, a key component of the project, promises faster speeds and reduced heat in AI computing. Leaders at ENZC and SAGA express optimism about the technology's transformative potential in various industries, particularly medical diagnostics and imaging.
On May 22, 2024, Enzolytics announced a Letter of Intent with Enogenesis to exclusively license a patented Nitric Oxide Compound (NOC) for therapeutic use. The initial market focus includes combining NOC with Virogentics' nutraceutical products like IPF Immune. The NOC formulation can be used in various forms, including drops, pills, or sprays. Additionally, Virogentics is starting the pharmacokinetics investigation for ITV-1 in Europe. Enzolytics believes incorporating NOC with Metformin may enhance diabetes treatment, reducing adverse effects and improving drug delivery. They aim to commercialize these products quickly. SAGA, Virogentics' parent company, is expanding its product categories and pursuing a $25 million grant to support this venture.
Enzolytics, Inc. announced the formation of ETC Marketing Inc. in partnership with Third Coast Fulfillment to focus on licensing medical devices, nutraceuticals, and other health products. ETC Marketing will invest in digital marketing and AI technology to engage with consumers and minimize costs. The partnership aims to expand Sagaliam's product categories and distribution channels.
